Kenta Yoshida

3.6k total citations
64 papers, 2.4k citations indexed

About

Kenta Yoshida is a scholar working on Oncology, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Kenta Yoshida has authored 64 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 24 papers in Pharmacology and 23 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Kenta Yoshida's work include Drug Transport and Resistance Mechanisms (26 papers), Pharmacogenetics and Drug Metabolism (22 papers) and Pharmacological Effects and Toxicity Studies (19 papers). Kenta Yoshida is often cited by papers focused on Drug Transport and Resistance Mechanisms (26 papers), Pharmacogenetics and Drug Metabolism (22 papers) and Pharmacological Effects and Toxicity Studies (19 papers). Kenta Yoshida collaborates with scholars based in United States, Japan and France. Kenta Yoshida's co-authors include Yuichi Sugiyama, Kazuya Maeda, Toshiharu Horie, Yoshihisa Shitara, Hiroyuki Kusuhara, Vikram Arya, Ping Zhao, Aleksandra Galetin, Yurong Lai and Shiew‐Mei Huang and has published in prestigious journals such as Journal of the American Chemical Society, Hepatology and Clinical Cancer Research.

In The Last Decade

Kenta Yoshida

61 papers receiving 2.4k citations

Peers

Countries citing papers authored by Kenta Yoshida

Since Specialization

Citations

This map shows the geographic impact of Kenta Yoshida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenta Yoshida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenta Yoshida more than expected).

Fields of papers citing papers by Kenta Yoshida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenta Yoshida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenta Yoshida. The network helps show where Kenta Yoshida may publish in the future.

Co-authorship network of co-authors of Kenta Yoshida

This figure shows the co-authorship network connecting the top 25 collaborators of Kenta Yoshida. A scholar is included among the top collaborators of Kenta Yoshida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenta Yoshida. Kenta Yoshida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bridging in vitro and clinical data: Experimental insights into the IC50 variability of dolutegravir as an organic cation transporter 2 inhibitor 2025 ·Drug Metabolism and Disposition ·(unknown), (unknown), (unknown), Kunal S. Taskar, Kenta Yoshida, (unknown), Tadayuki Takashima, Yurong Lai, Yuichi Sugiyama, Hiroyuki Kusuhara	1
2	Quantifying Risk of Delayed QT Prolongation of Ipatasertib in Preclinical and Clinical Studies in Cancer Patients 2025 ·Clinical and Translational Science ·(unknown), Dhruvitkumar S. Sutaria, Rodney A. Prell, Wendy Halpern, (unknown), Adam Harris, Justin Wilkins, Kenta Yoshida, Rucha Sane	1
3	The closure of microcracks under pressure: inference from elastic wave velocity and electrical conductivity in granitic rocks 2024 ·Earth Planets and Space ·Tohru Watanabe, (unknown), Kenta Yoshida	0
4	Simulation‐based evaluation of personalized dosing approaches for anti‐FGFR/KLB bispecific antibody fazpilodemab 2024 ·CPT Pharmacometrics & Systems Pharmacology ·Kenta Yoshida, (unknown), Ajit Dash, Rebecca Kunder, Leslie W. Chinn, Matts Kågedal	4
5	Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models 2023 ·British Journal of Cancer ·René Bruno, Pascal Chanu, Matts Kågedal, François Mercier, Kenta Yoshida, Jérémie Guedj, Chunze Li, Ulrich Beyer, Jin Y. Jin	13
6	Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150 2023 ·Clinical Cancer Research ·René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, François Mercier, Pascal Chanu, Benjamin Wu, (unknown), Chunze Li, Jin Y. Jin, Michael L. Maitland, Martin Reck, Mark A. Socinski	13
7	Concentration QTc analysis of giredestrant: Overcoming QT/heart rate confounding in the presence of drug‐induced heart rate changes 2023 ·Clinical and Translational Science ·(unknown), (unknown), (unknown), Kenta Yoshida, (unknown), Vikram Malhi, Chunze Li, Pablo Ernesto Pérez, J. Richard Bond, (unknown), Jiajie Yu	2
8	Applications of Advanced Natural Language Processing for Clinical Pharmacology 2023 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), (unknown), Bianca Vora, (unknown), (unknown), Kenta Yoshida, (unknown), (unknown), Jin Y. Jin, Christina Lu, (unknown), Benjamin Wu	8
9	Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs 2022 ·Clinical and Translational Science ·Tatsuki Mochizuki, Yasunori Aoki, Takashi Yoshikado, Kenta Yoshida, Yurong Lai, Hideki Hirabayashi, Yoshiyuki Yamaura, Kevin Rockich, Kunal S. Taskar, Tadayuki Takashima, Xiaoyan Chu, Maciej J. Zamek‐Gliszczynski, (unknown), Kazuya Maeda, Kenichi Furihata, Yuichi Sugiyama, Hiroyuki Kusuhara	24
10	Clinical Relevance of Hepatic and Renal P‐gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective 2022 ·Clinical Pharmacology & Therapeutics ·Kunal S. Taskar, Xinning Yang, Sibylle Neuhoff, Mitesh Patel, Kenta Yoshida, Mary F. Paine, Kim L. R. Brouwer, Xiaoyan Chu, Yuichi Sugiyama, Jack Cook, Joseph W. Polli, Imad Hanna, Yurong Lai, Maciej J. Zamek‐Gliszczynski, (unknown)	23
11	Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study 2022 ·The AAPS Journal ·Kenta Yoshida, Phyllis Chan, Mathilde Marchand, Rong Zhang, Benjamin Wu, Marcus Ballinger, (unknown), Jin Y. Jin, René Bruno	4
12	Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework 2021 ·CPT Pharmacometrics & Systems Pharmacology ·Phyllis Chan, Mathilde Marchand, Kenta Yoshida, Shweta Vadhavkar, Na Wang, (unknown), Benjamin Wu, Marcus Ballinger, (unknown), Jin Y. Jin, René Bruno	24
13	Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease 2020 ·Alzheimer s Research & Therapy ·Kenta Yoshida, (unknown), Tobias Bittner, Susanne Ostrowitzki, Helen Lin, Lee Honigberg, Jin Y. Jin, Angelica Quartino	37
14	GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study 2019 ·Drug Metabolism and Disposition ·(unknown), Kenta Yoshida, Sravanthi Cheeti, Buyun Chen, Roland Morley, Iris T. Chan, Srikumar Sahasranaman, Lichuan Liu	28
15	Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium 2018 ·Clinical Pharmacology & Therapeutics ·Xiaoyan Chu, Mingxiang Liao, Hong Shen, Kenta Yoshida, Arik A. Zur, Vikram Arya, Aleksandra Galetin, Kathleen M. Giacomini, Imad Hanna, Hiroyuki Kusuhara, Yurong Lai, David Rodrigues, Yuichi Sugiyama, Maciej J. Zamek‐Gliszczynski, Lei Zhang	161
16	Accurate Estimation of In Vivo Inhibition Constants of Inhibitors and Fraction Metabolized of Substrates with Physiologically Based Pharmacokinetic Drug–Drug Interaction Models Incorporating Parent Drugs and Metabolites of Substrates with Cluster Newton Method 2018 ·Drug Metabolism and Disposition ·Kenta Yoshida, Kazuya Maeda, Akihiko Konagaya, Hiroyuki Kusuhara	8
17	Clinical Drug–Drug Interaction Evaluations to Inform Drug Use and Enable Drug Access 2017 ·Journal of Pharmaceutical Sciences ·Dinko Rekić, Kellie S. Reynolds, Ping Zhao, Lei Zhang, Kenta Yoshida, Madhav Sachar, Micheline Piquette‐Miller, Shiew‐Mei Huang, Issam Zineh	47
18	Transporter-Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies 2012 ·Clinical Pharmacology & Therapeutics ·Kenta Yoshida, Kazuya Maeda, Yuichi Sugiyama	133
19	Effect of Coadministration of Single and Multiple Doses of Rifampicin on the Pharmacokinetics of Fexofenadine Enantiomers in Healthy Subjects 2012 ·Drug Metabolism and Disposition ·Hiroyuki Kusuhara, Masatomo Miura, Norio Yasui‐Furukori, Kenta Yoshida, Yumiko Akamine, M Yokochi, (unknown), (unknown), (unknown), Tsukasa Uno, Yuichi Sugiyama	34
20	THE EFFECTS OF LOWER FLANGE SLOPE ON THE AERODYNAMIC STABILITY OF A PENTAGONAL CROSS-SECTION GIRDER 2009 ·Doboku Gakkai Ronbunshuu A ·(unknown), (unknown), (unknown), (unknown), (unknown), Kenta Yoshida	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact